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Abstract 
 
 
In response to physiological cold temperatures, cutaneous blood vessels constrict 
to reduce heat loss. This constriction is mediated by smooth muscle G protein-coupled 
α2C-adrenoceptors (α2C-ARs), which translocate from the trans-Golgi to the plasma 
membrane upon cooling. The cellular mechanisms involved in receptor translocation are 
not fully understood; however, this translocation is hypothesized to be dependent upon a 
protein-protein interaction between the α2C-AR C-terminus and the protein filamin-2. 
This portion of the receptor translocation mechanism can be tested experimentally by 
decoy peptide interference. 
The decoy peptide contains a TAT domain and an identical C-terminus to the α2C-
AR, allowing the peptide to penetrate the cell membrane and mimic the α2C-AR, 
respectively. We predict that interfering with this interaction will inhibit translocation of 
α2C-ARs and subsequent receptor function. Therefore, the goal of this study is to generate 
and purify a decoy peptide, confirm delivery to human VSM cells, and assess cellular 
activity for endogenous α2C-ARs. 
The DNA sequence encoding 11 amino acids of the cell-permeable HIV 
transactivator of transduction (TAT) domain was fused in frame with the α2C-AR C-
terminus to generate the p-TAT-α2C-AR-C-terminus bacterial expression vector. BL21-
CodonPlus competent cells were used to optimize peptide expression at 30°C. The 
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parameters tested during bacterial growth included the presence of antibiotics, induction 
time, and growth temperature. Additionally, cell lysis, sonication and salt precipitation 
conditions were optimized. Peptide expression was confirmed by Western blot and 
Coomassie techniques. The peptide was purified by ammonium sulfate, ion-exchange 
chromatography and nickel column techniques. The peptide was successfully delivered to 
human VSM and HEK-293 cells, confirmed by microscopic visualization and western 
blot techniques, which will be utilized to assess activity of endogenous α2C-ARs. 
Additionally, these studies have broader implications for understanding the role of actin 
in protein translocation and cell surface delivery.
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Chapter 1: Introduction 
1.1 α2C-Adrenoceptors (α2C–ARs) 
 Vascular smooth muscle cells, such as those found in arteries, arterioles and veins, are 
constriction regulated by a family of G protein coupled receptors known as α2-adrenoceptors (α2-
ARs). These receptors are separated into three classifications based on their structure and 
physiological function, denoted α2A, α2B, and α2C. Previous studies show that the majority of 
vascular constriction is regulated by α2A and α2B activity (MacDonald, Kobilka and Scheinin). 
Recent studies indicate that α2C-ARs are responsible for constriction induced specifically by 
physiologically cold temperatures (Chotani, Mitra and Su). Collectively, experiments correlate 
high levels of vascular constriction with increased levels of α2-AR activity (Chotani, Flavahan 
and Mitra). 
 Blood vessels at the periphery of the body conserve heat by constricting upon exposure to 
cold temperatures, which reduces blood flow to the extremities and therefore an organism’s heat 
loss. During physiologically warm temperature (37˚C experimentally), α2C–AR activity is 
silenced because of its intracellular location in the Golgi apparatus (Jeyaraj, Chotani and Mitra). 
Upon cold exposure, α2C-ARs trans-locate to the plasma membrane, where they engage with the 
agonist and are activated. When cold stimulus is removed, the α2C–ARs are no longer functional, 
and the blood vessels dilate to their relaxed state (Chotani, Flavahan and Mitra). 
 Certain individuals are prone to vessel dysfunction, causing the vessels to remain 
constricted. A result of this cellular dysfunction is Raynaud’s phenomenon, a disease in which 
blood flow is reduced to extremities following cold exposure, leading to discoloration, atrophy of 
the skin, and potentially more severe consequences (Flavahan, Flavahan and Mitra). This vessel 
dysfunction is likely related to increased α2C–AR activity; therefore, understanding the cellular 
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mechanism of cold induced blood vessel constriction may lead to a pharmaceutical treatment of 
this disease. 
 Sub-cellular protein retention is due to the amino acid motif “RXR”, R being arginine 
and X being any amino acid. The α2C–AR fits the proposed mechanism with a stretch of amino 
acids “RRRRR” (Eid, Molecular Regulation of Vascular α2C- Adrenoceptors). However, the 
α2C–AR is of particular interest because it re-locates to the membrane upon cooling. The 
mechanism of trans-location is yet to be determined and is the focus of our research. 
 The α2–AR family of proteins contains a trans-membrane spanning domain along with 
several other conserved amino acid sequences. However, the α2C–AR most significantly differs 
from the α2–AR family of proteins in the C-terminus. Therefore, the α2C–AR C-terminus was 
utilized in a yeast two-hybrid approach, effectively identifying a novel protein-protein interaction 
with the actin binding protein, filamin-2 (MA Chotani, unpublished results). The strong affinity 
of α2C–AR C-terminus to filamin-2 indicates that trans-location may depend upon their 
interaction, which leads to the utilization of a decoy peptide. 
1.2 Decoy Peptide 
 A decoy peptide serves to mimic the α2C–AR, specifically the C-terminal sequence 
hypothesized to be responsible for receptor trafficking via binding to filamin-2. To utilize this 
technique, the cell is loaded with an excess of the decoy peptide, effectively saturating the 
binding sites to filamin-2 and limiting α2C–AR binding capabilities. The general procedure for 
obtaining this peptide in an experimentally useful form is outlined by the following steps: DNA 
cloning, bacterial transformation, bacteria growth, transcription induction, cell lysis, and peptide 
purification.  
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 During expression of heterologous peptides in E. Coli, cells frequently interpret peptides 
as potentially harmful. As a result, the bacteria form inclusion bodies around the peptide, which 
are insoluble, micelle-like structures. However, for a successful purification, it is important to 
express the peptide in a soluble form. The formation of inclusion bodies is a major obstacle 
because it prohibits soluble expression and purification. 
 A critical component of the decoy peptide is the TAT domain, which allows the 
successful transduction of full length proteins into primary and transformed cells. The TAT 
amino acid sequence is derived from the cell-permeable HIV transactivator of transduction, 
which is a DNA sequence encoding 11 amino acids (Becker-Hapak, McAllister and Dowdy). 
The proposed mechanism of cellular entry via the TAT amino acid sequence is 
macropinocytosis, in which a sequence of highly charged arginine residues binds to heparin 
sulfate on the cell membrane of an actin protrusion. The process of peptide entry is non-passive, 
indicating that molecules stimulate their own endocytosis. Not much is known about the 
degradation of large endosomes inside the cell, however it is likely due to chemical, potential, or 
pH gradients along the endosome path to the Golgi (Gump and Dowdy). 
1.3 Hypotheses 
 Our hypothesis is that the interaction of the α2C-AR C-terminus with filamin-2 is 
necessary for its translocation from the Golgi to the cell surface. Interference with α2C-AR 
binding to filamin-2 will inhibit the localization of α2C–AR to the cell surface and subsequent 
biological activity.  
 At warm temperatures (37°C), we expect to see no changes in the activity of α2C–AR. 
Upon cooling, interference with filamin-2 will reduce the re-localization of α2C–AR to the cell 
surface compared to control cells without the decoy peptide.   
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efficiency. Maximum transformation efficiency is observed using 0.1 ng DNA, and maximum 
yield is observed when using 50 ng DNA.  
BL-21 CodonPlus (DE3)-RIPL competent cells were used for transformation because 
they contain extra copies of tRNAs that enhance expression of heterologous proteins. The 
transformations were performed according to manufacturer recommended protocol. The entirety 
of the transformation protocol can be seen in the instruction manual for BL21 Competent Cells 
(Stratagene, Cat # 200131 Rev #066004e).  
 The plasmid DNA and competent cell solution set on ice for 30 minutes, which allowed 
the diffusion of DNA into the permeated membrane. To close the cell membrane, the cells were 
heat pulsed at 42˚C for 20 seconds and placed on ice for 2 minutes. The cells were grown in pre 
heated SOC medium (42˚C), and finally the cells were spread onto LB agar plates with the 
antibiotics ampicillin and chloramphenicol. The pTAT-HA expression vector and the competent 
cell host strain contained genes encoding ampicillin and chloramphenicol resistance, 
respectively. The dual antibiotic treatment allowed selective growth of bacteria that contained 
genes encoding the decoy peptide and transcription factors. The successfully transformed 
bacteria colonies were made into glycerol stocks for long term storage. To create glycerol stocks, 
equal volumes of the bacteria solution and 50% sterile glycerol were mixed, vortexed, and stored 
at -80 ˚C.  
2.3 Bacteria Growth 
 Bacteria growth was performed using freshly transformed bacteria colonies or glycerol 
stocks once their peptide integrity was confirmed. Bacteria colonies were grown in three steps, as 
described here. Small amounts of frozen bacteria from the glycerol stocks were grown on LB 
agar plates, which were pre-treated with ampicillin and chloramphenicol. Individual colonies 
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from the plate were selected and inoculated in 3 mL of Luria Broth (LB Broth, Appendix A) with 
both antibiotics (37˚C, 225 RPM shaking). Finally, the bacteria colonies were added to 0.5 – 2.0 
liters of LB broth with antibiotics. The variables tested for effect on bacteria growth were 
temperature, the presence of antibiotics, and the presence of the chemical isopropyl β-D-1-
thiogalactopyranoside (IPTG). 
2.4 Transcription Induction 
 Induction was performed using Isopropyl β-D-1-thiogalactopyranoside (IPTG, 1 mM), a 
molecular mimic of allolactose that triggers transcription of the lac operon. The pTAT vector 
contained the T7 lac promoter, allowing high levels of peptide expression upon induction. 
Bacterial expression levels were tested with variable bacteria growth temperatures and 
concentrations, the presence of chloramphenicol, the length of induction, and the type of broth, 
as will be discussed in the results.  
2.5 Cell Lysis 
 Lysis was accomplished via sonication, which utilized ultrasonic waves to disrupt the cell 
membrane. Bacteria colonies were pelleted from their growth media (3000 RCF, 4˚C), re-
suspended in a lysis buffer and sonicated (Appendix B). The product solution was centrifuged 
(40,000 RCF), and the supernatant and precipitate were tested separately for peptide content. 
Highly soluble peptide expression was necessary before purification was possible; therefore, 
various conditions that effect cell lysis were tested. The parameters optimized to ensure 
maximum soluble recovery included utilization of a freeze-thaw protocol, and analyses of 
sonication levels, lysis buffers, and the bacteria growth temperature.  
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2.6 Peptide Purification 
 The first purification scheme utilized ammonium sulfate precipitation followed by ion-
exchange chromatography. Urea was added to the lysate solution (6 M). The salt concentration 
was incrementally increased to 30%, 50%, and 70% of saturation (Appendix C). At low salt 
concentrations, hydrophobic peptides precipitated from solution. At each increment, the solution 
was centrifuged, the precipitate was separated and re-suspended into fresh buffer, the solution 
was dialyzed and a sample was analyzed for peptide content (Appendix C).  
 The fraction containing the decoy peptide was further purified using ion-exchange 
chromatography. The theoretical isoelectric point of the decoy was 11.5, resulting in a positively 
charged molecule at a pH of 8. The peptide solution (pH 8) was sent through anion exchange 
(positively charged resin), where negatively charged peptides were retained, but the peptide of 
interest flowed through. The flow through solution was then sent through cation exchange 
(negatively charged resin), where negative/ neutral peptides flowed through the column, but the 
peptide of interest was retained. The column was eluted by increasing the salt concentration 
along a gradient of a solution flowing through the column at a constant flow rate. Fractions were 
collected along the salt concentration gradient, and the effluent samples were tested for peptide 
content (Appendix D). 
 The second purification was accomplished by a nickel column. The histidine tag on the 
decoy peptide gave strong affinity for positively charged metal ions, such as nickel. The peptide 
solution was run through a column filled with nickel resin. The majority of cell contents passed 
through, but the peptide of interest was retained. The peptide was eluted by increasing the 
imidazole concentration of a flowing solution. The effluent samples were tested for peptide 
content (Appendix E). 
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2.7 Cellular Transduction 
 The peptide solutions were exposed at various concentrations to mouse tail VSMs and 
HEK-293 cells. Cell imaging was performed following transduction into VSMs with DAPI 
(blue) for nucleus visualization and AlexaFluor-488 (green) for the HA tag on the decoy peptide. 
Successful delivery was confirmed using HEK-293 cells by exposure of the peptide solution for 
4 hours followed by washing of the cell membrane prior to Western blot analysis. 
2.8 Western Blot and Coomassie Techniques 
 The presence of the decoy peptide in a given sample was detected using Western blot and 
Coomassie techniques (Appendix F). When performing a Western blot, the samples were run in 
an 18% poly-acrylamide gel and transferred to a polyvinylidene fluoride (PVDF) membrane. The 
commercially available HA primary antibody was exposed to the membrane at a 1:1000 dilution, 
and the anti-mouse HRP secondary antibody was exposed at a 1:2000 dilution. To confirm the 
results, a custom synthesized α2C–AR C-terminus primary antibody (Chotani, Mitra and Su) was 
used at a 1:1000 dilution with secondary anti-rabbit HRP at a 1:2000 dilution.  
 Coomassie staining was used directly on the poly-acrylamide gel, which gave the total 
peptide content. The results of Coomassie and Western blots were used in conjunction to 
determine the presence of peptide and a rough estimate for the quantity of expression. 
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growth conditions. Levels of expression were examined after induction at 0.2 angstroms. Figure 
7 displays the results using LB and TB growth media. The levels of expression were identical, 
and LB broth was used moving forward because of the higher cost associated with enriched TB 
growth media. 
 
Figure 7: Induction in LB Broth and TB Broth 
3.5 Cell Lysis 
 Heterologous proteins expressed in E. Coli may remain insoluble for two main reasons: 
insufficient cell lysis, or the formation of inclusion bodies around the peptide As mentioned, 
soluble expression was critical for a successful purification; therefore, various lysis conditions 
were examined. To test for sufficient lysis, the utilization of a freeze thaw protocol prior to 
sonication was tested. Integration of a freeze/thaw technique would weaken the cell membrane, 
allowing for an effective lysis via sonication. The results for the freeze/thaw protocol can be seen 
in Figure 8. A “+” indicates a freeze/thaw protocol was utilized. 
 
Figure 8: Soluble Expression (+/-) Utilization of Freeze Thaw 
LB TB 
+ - + 
Supernatant Precipitate 
Bacteria Growth at (37 ˚C) 
-
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 Comparing the levels of expression in the supernatant and precipitate during normal and 
freeze/thaw conditions indicated that an identical distribution of peptide resided in each sample 
whether or not the freeze/thaw procedure was included. Our conclusion was that the cells were 
sufficiently lysed without the freeze/thaw; therefore, the formation of inclusion bodies was 
further considered. 
 To test the formation of inclusion bodies, bacteria colonies were grown and induced at 
37˚, 30˚, and 20˚C. Soluble expression levels were qualitatively measured using Western blots. 
The results can be seen in Figure 9. 
 
Figure 9: Soluble Expression at Various Temperatures 
 In general, high temperatures showed the highest level of overall expression but also the 
highest level of insoluble expression. Low temperatures showed an improved distribution of 
peptide in a soluble form; however, the total level of expression decreased. These results support 
the idea that inclusion bodies were the reason behind insoluble expression. Low temperatures 
decreased the thermodynamic stability of micelle-like formations; therefore increasing the 
effectiveness of sonication. However, decreased temperatures slowed bacteria growth; therefore 
decreasing total expression. A growth temperature of 30˚C was utilized to balance between 
soluble and total expression. 
 
 
 
Sup Ppt Sup Ppt Sup Ppt 
37˚C 30˚C 20˚C 
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3.6 Peptide Purification 
3.6.1 Salt Precipitation 
Upon achieving soluble peptide expression, ammonium sulfate precipitation was used to 
purify 50-70% of the undesired contents from solution. The results for Coomassie and Western 
blot techniques can be seen in Figure 10 below. The decoy peptide only showed a signal in the 
50-70% fraction; therefore this fraction was further purified using ion exchange chromatography. 
 
Figure 10: Ammonium Sulfate Precipitation Samples 
3.6.2 Ion Exchange Chromatography 
 Ion exchange chromatography was utilized to yield a solution of 90-95% purity. The first 
column was filled with positively charged resin, and the results from the first column can be seen 
in Figure 11. As expected, the positively charged peptide was present in the flow through (FT). 
 
Figure 11: Ion Exchange Chromatography Column 1 Results 
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The flow through solution was sent through to a second, negatively charged column, and 
the peptide was retained in the resin. A solution with increasing salt concentration was sent 
through the second column to elute the peptide. Figure 12 shows the samples that were collected 
along the salt gradient.  
 
Figure 12: Ion Exchange Chromatography Column 2 Results 
 
Figure 12: Ion Exchange Chromatography Column 2 Results 
The blue line measured the detection of a tryptophan amino acid, indicating that a peptide 
had been eluted from the column. The collected fractions near an amino acid peak were tested 
for protein content using Western blots. The Western blot signal, which can also be seen in 
Figure 12, is aligned directly below the fraction being tested. The results indicated that several 
fractions surrounding the peak in sample “33” contained the peptide. These samples were 
dialyzed, lyophilized, and re-suspended in buffer so they could be tested for delivery to vascular 
smooth muscle cells. 
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3.6.3 Nickel Column 
 A nickel column was also used to purify the peptide. This technique directly purified the 
lysed bacteria solution, and the results can be seen in Figure 13.  
 
Figure 13: Nickel Column Purification Results 
 The total peptide content was equivalent to a combination of the supernatant and 
precipitate. Similarly, the total peptide content was equivalent to the flow through sample 
combined with the purified fractions. This procedure was much faster than the first purification 
method; however, the purity yield was not as high.  
3.7 Cellular Transduction 
 The fractions purified by the nickel column were tested for delivery to mouse tail 
vascular smooth muscle cells (VSMs) and HEK-293 cells. The results can be seen in Figure 14 
and Figure 15, respectively. The peptide was directly exposed to VSMs at a range of volumes, 
and these cells were tested for successful delivery using microscopic visualization. Figure 14 
shows a strong positive signal in VSMs that were exposed to the decoy. Quantitatively, the 
signal was twice as intense for the cells containing the delivered peptide as the control.  
 
Total Peptide 
Content 
Purified Fractions Sup   Ppt   FT
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Figure 14: Microcsopic Visualization of Peptide Delivery to Mouse Tail Artery VSMs 
 
Figure 14 (continued): 3D-construction of images acquired in z-stacks, mouse tail artery VSMs. The arrows point to 
intracellular localization of signal in “TAT-α2C peptide” cells compared to “Control” cells without peptide. Blue stain 
(DAPI) nucleus. 
 These results were confirmed by delivery to HEK-293 cells (Figure 15). The peptide was 
exposed to the cell membrane and allowed 4-6 hours for transduction. The membrane was 
washed; therefore any signal would indicate successful uptake by the cell. A strong signal was 
seen in a Western blot of the sample with decoy delivery; however, the control showed no signal. 
 
Control  TAT-α
2C
 Delivery 
Control
TAT-α2C peptide
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Figure 15: Western Blot of Peptide Delivery to HEK-293 Cells 
 
 
Control TAT-α
2C
 Delivery 
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Chapter 4: Conclusions and Recommendations 
 This thesis has shown the successful expression and purification of a peptide that is to be 
used for testing the mechanism of cold induced vascular constriction. Additionally, successful 
delivery of the peptide was demonstrated to mouse tail VSMs and HEK-293 cells.  
 Throughout the peptide expression process, several bacteria growth conditions were 
optimized. Growth at 30 ˚C limited the stability of inclusion bodies formed by bacteria defenses, 
therefore allowing soluble expression following sonication. Induction was performed strictly 
during the logarithmic bacteria growth phase, limiting the degradation of protein that occurred 
following non-ideal growth conditions. Utilization of freeze/thaw techniques and enriched 
growth media had negligible effects on peptide expression. 
 Peptide purification was performed using ammonium sulfate precipitation, ion exchange 
chromatography and nickel column techniques. During salt precipitation, the decoy peptide was 
present in a 50-70% ammonium sulfate saturation fraction. Ion exchange chromatography and 
nickel columns successfully purified the peptide, and the nickel column purified peptide tested 
for cell-delivery. Successful delivery to mouse tail VSMs and HEK-293 cells was confirmed 
using microscopic visualization, intensity comparisons, as well as Western blot techniques. 
 A cold exposure analysis using the decoy peptide is the next step to the process. As 
indicated, decoy will be used to tie up the binding sites to the actin binding filamin-2, effectively 
localizing the α2C–AR in its sub-cellular location. Additionally, the effect of domain swapping 
the C-termini of the α2C– and α2A–ARs generating receptor chimera will provide additional 
insight on the role of the C-terminus in receptor trafficking. 
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Appendix A: Types of Broth 
Table 1: Luria Broth Composition (Sigma-Aldrich) 
Chemical Concentration 
Tryptone 10 g/L 
Yeast Extract 5 g/L 
NaCl 10 g/L 
 
Table 2: Luria Broth Preparation Instructions 
1. Suspend 25 g of Luria Broth base in 1 L distilled water 
2. Autoclave for 15-20 minutes at 121 ˚C  
3. Allow to cool to the touch, and add antibiotics 
 
Table 3: Terrific Broth Composition (Sigma Aldrich) 
Chemical Concentration 
Tryptone 12 g/L 
Yeast Extract 24 g/L 
K2HPO4 9.4 g/L 
KH2PO4 2.2 g/L 
 
Table 4: Terrific Broth Preparation Instructions 
1. Suspend 47.6 g of Terrific Broth base, 8 mL glycerol in 1 L distilled water 
2. Autoclave for 15-20 minutes at 121 ˚C 
3. Allow to cool to the touch, and add antibiotics 
 
  
27 
 
Appendix B: Lysis Buffers and Conditions 
Cell were pelleted from their growth media and re-suspended in a lysis buffer. Generally, in a 
solution of 1 L cells in growth media, the pelleted cells were re-suspended in 50 mL lysis buffer.  
Table 5: Sucrose (STE) Lysis Buffer Composition 
Chemical Concentration 
Sucrose 0.5 g/L 
EDTA 1 mM 
Tris-HCl pH 8.0 20 mM 
Protease Inhibitors 1x 
 
Table 6: Urea Lysis Buffer Composition 
Chemical Concentration 
Urea 6 M 
EDTA 1 mM 
Tris-HCl pH 8 20 mM 
NaCl 1 M 
Protease Inhibitors 1x 
 
Table 7: Sonication Procedure 
1. Bacteria solution is pipetted into 50 mL conical vial 
2. Optional addition of anti-foam suspension to top surface of bacteria solution 
3. Solution is sonicated for 20 seconds on medium power 
4. Solution is allowed to settle for 40 seconds 
5. Steps 3-4 are repeated 5 additional times 
6. Sonicate solution is ultracentrifuged at 40,000 RCF, 4 ˚C for 20 minutes 
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Appendix C: Ammonium Sulfate Precipitation Conditions 
Table 8: Ammonium Sulfate Additions for Certain Saturation Levels (%) at 0 ˚C 
Percent Saturation Amount of Salt Addition 
0-30% 16.6 g / 100 mL 
30-50% 11.9 g / 100 mL 
50-70% 12.7 g / 100 mL 
 
Table 9: Dialysis Buffer Composition 
Chemical Concentration 
Urea 6 M 
EDTA 1 mM 
Tris pH 8.0 20 mM 
 
Table 10: Ammonium Sulfate Precipitation Procedure 
1. Ammonium sulfate added to certain level of concentration (e.g. 30%) 
2. Sample spun down at 40,000 RCF for 20 min 
3. Precipitate separated from solution and re-suspended in Dialysis Buffer 
4. Suspension homogenized if necessary 
5. Steps 1-4 repeated to the supernatant solution at the next concentration (e.g. 50%) 
6. All solutions dialyzed in a total of 1 L of fresh dialysis buffer for 12 hours 
7. Step 6 repeated 
8. All samples tested for peptide content 
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Appendix D: Ion Exchange Chromatography Purification Conditions 
Table 11: Column Exchange Buffer 
Chemical Concentration 
Urea 6 M 
EDTA 1 mM 
Tris pH 8.0 20 mM 
 
Table 12: Column Elution Buffer 
Chemical Concentration 
Urea 6 M 
EDTA 1 mM 
Tris pH 8.0 20 mM 
NaCl 1 M 
 
Table 13: Ion Exchange Chromatography Protocol 
1. Buffers vacuum filtered and de-gassed 
2. Peptide solution syringe filtered (44 um) and re-suspended in exchange buffer 
3. Sample flow through column 1 (Q-seph) 
4. Sample flow through column 2 (Source 15s) 
5. Elution with buffer, fractions collected 
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Appendix E: Nickel Column Purification 
Table 14: Sonication Buffer 
Chemical Concentration 
NaCl 0.5 M 
Tris HCl pH 7.4-8.5 20 mM 
Imidazole 50 mM 
 
Table 15: Elution Buffer 1 
Chemical Concentration 
NaCl 0.5 M 
Tris HCl pH 7.4 10 mM 
Imidazole 0 mM 
 
Table 16: Elution Buffer 2 
Chemical Concentration 
NaCl 0.5 M 
Tris HCl pH 7.4 20-50 mM 
Imidazole 100 mM 
 
Table 17: Elution Buffer 3 
Chemical Concentration 
NaCl 0.5 M 
Tris HCl pH 7.4 20-50 mM 
Imidazole 500 mM 
 
Table 18: Nickel Column Purification Procedure 
1. Cells re-suspended in sonication buffer, sonicated, and spun down at 20,000 RCF. 
2. 2.5 mL nickel resin added to plastic column with filter  
3. Fresh sonication buffer flows through column at 5 times volume of resin (12 mL) 
4. Column is capped, supernatant from sonication is poured into column, cap removed  
5. After flow, column washed with 10 times column volume with elution buffer 1 
6. Next, column is washed with 20 mL with fresh sonication buffer 
7. Elution samples are checked for peptide content with color change in Bradford Reagent. 
To test with Bradford reagent, 30 uL reagent is added to 10 uL sample 
8. Following elution with buffer 1, column is eluted with 2 times column volume with 
buffer 2 (5 mL). This is performed 1 mL at a time 
9. Column is eluted with 1 mL buffer 3, repeated x6 
10. Fractions are collected, tested with Bradford reagent, and utilized with Western Blot 
11. Column is regenerated by washing with 10 times column volume with distilled water, 2 
times the column volume with 0.5 M NaOH, and final wash with distilled water. 
12. To increase peptide purity, NaCl concentration can increase to 1 M in all buffers 
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Appendix	F:	Peptide	Visualization	Using	Western	Blot	and	Coomassie	
Table 19: SDS Lysis Buffer 
Chemical Concentration 
Tris HCl pH 7.0 60 mM 
SDS 2% 
 
Table 20: 10 X Transfer Buffer (2L) 
Chemical Mass 
Glycine 180 g 
Tris Base 38.6 g 
Water 2 L 
 
Table 21: 1X Transfer Buffer (4L) 
Chemical Volume 
10X Transfer Buffer 400 mL 
Methanol 800 mL 
Water 2800 mL 
 
Table 22: TBS / Tween 
Chemical Concentration 
Tris HCl pH 7.5 10 mM 
NaCl 150 mM 
Tween-20 0.1 % 
 
Table 23: Blocking Solution 
Chemical Concentration 
Non Fat Dry Milk 5% (5 g / 100 mL) 
TBS / Tween Solvent 
 
Table 24: Western Blot and Coomassie General Protocol 
1. Samples were mixed with 5X SDS loading dye in a 4:1 ratio  
2. Samples were boiled at 75 ˚C for 10 minutes and spun down at 10,000 RCF for 2 minutes 
3. Criterion, 18% tris-HCl gels were utilized with TGS Running Buffer 
4. Current was set to 70 volts during stacking section, then 150 V until sufficient separation 
5. Coomassie staining could be performed directly after running the gel. For a detailed 
protocol, see specific manufacturer instructions (give reference to manufacturer here) 
6. For Western Blot visualization, gel peptides were transferred to the PVDF membrane 
using 1X transfer buffer. PVDF membrane was activated in methanol for 30 seconds 
prior to transfer. 
7. Transfer current was set to 25 volts, which ran overnight. 
8. Following Transfer, membrane was stained with Napthol Blue Black to achieve 
preliminary peptide content visualization for successful transfer. 
9. Following Napthol staining, membrane was washed thoroughly with water, and then 
exposed to blocking solution for 1 hour 
10. Membrane exposed to primary antibody solution for 1 hour with rocking 
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11. Membrane washed with TBS / Tween for 20 minutes, repeated twice (rocking) 
12. Membrane exposed to secondary antibody solution for 1 hour (rocking) 
13. Membrane washed with TBS / Tween for 20 minutes, repeated three times (rocking) 
14. Chemiluminescent reaction performed on membrane using hydrogen peroxide, luminol, 
and perioxidase enzyme on secondary antibody 
15. Membrane exposed to X-Ray film in dark room, and film processed. 
16. Peptide content leads to signal on X-Ray film 
 
